Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumors carrying BRAF-mutations over-express NAMPT that is genetically amplified and possesses oncogenic properties.

Journal of translational medicine - 10 Mar 2022

Audrito Valentina, Moiso Enrico, Ugolini Filippo, Messana Vincenzo Gianluca, Brandimarte Lorenzo, Manfredonia Ilaria, Bianchi Simonetta, De Logu Francesco, Nassini Romina, Szumera-Ciećkiewicz Anna, Taverna Daniela, Massi Daniela, Deaglio Silvia

Abstract excerpt

BACKGROUND: Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in nicotinamide adenine dinucleotide (NAD) biosynthesis, is up-regulated in several cancers, including metastatic melanoma (MM). The BRAF oncogene is mutated in different cancer types, among which MM and thyroid carcinoma (THCA) are prominent. Drugs targeting mutant BRAF are effective, especially in MM patients, even though...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinogenesis
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Copy Number Variations

Share to Melanoma

Share to Mutation

Share to Nicotinamide Phosphoribosyltransferase

Share to Oncogenes

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 35272691
DOI: 10.1186/s12967-022-03315-9
PMCID: PMC8908704

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumors carrying BRAF-mutations over-express NAMPT that is genetically amplified and possesses oncogenic properties.PMID 35272691Read ↗

NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in MelanomaSemantic proximity Read ↗

Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma.Semantic proximity Read ↗

Updated Functional Roles of NAMPT in Carcinogenesis and Therapeutic NichesSemantic proximity Read ↗

Pan-cancer analysis combined with experiments predicts NNMT as a therapeutic target for human cancersSemantic proximity Read ↗

NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic TargetsSemantic proximity Read ↗

NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC.Semantic proximity Read ↗

NAMPT: A critical driver and therapeutic target for cancerSemantic proximity Read ↗

Nicotinamide N-Methyltransferase: An Emerging Protagonist in Cancer Macro(r)evolutionSemantic proximity Read ↗

Nicotinamide N-Methyltransferase as Promising Tool for Management of Gastrointestinal NeoplasmsSemantic proximity Read ↗

NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.Semantic proximity Read ↗

Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors.Semantic proximity Read ↗

Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA RepairSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.